Fondaparinux: Difference between revisions
| Line 31: | Line 31: | ||
'''| [[Fondaparinux patient counseling information|Patient Counseling Information]]''' | '''| [[Fondaparinux patient counseling information|Patient Counseling Information]]''' | ||
'''| [[Fondaparinux labels and packages|Labels and Packages]]''' | '''| [[Fondaparinux labels and packages|Labels and Packages]]''' | ||
[[image:fonda1.png]] | |||
==Mechanism of Action== | ==Mechanism of Action== | ||
Revision as of 19:49, 3 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
For patient information, click here. Synonyms / Brand Names: Arixtra®
Overview
Fondaparinux (trade name Arixtra) is an anticoagulant medication chemically related to low molecular weight heparins. It is marketed by GlaxoSmithKline. A generic version developed by Alchemia is marketed within the US by Dr. Reddy's Laboratories.
Category
FDA Package Insert
Arixtra®
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
